OSD

Oncopeptides have collaborated with Recipharm to help bring their anti-cancer treatment to life.

Oncopeptides is a clinical stage company that is developing a molecule for oncologyindications. The molecule, which originated at Uppsala University, Sweden and the Karolinska Institute, is focused on multiple myeloma as a first indication.

Really good chemists are hard to come by. There are plenty that can follow recipes in a book but a very large part of chemistry is the ability to problem solve.

Myeloma is a very individual cancer, both in terms of what symptoms and complications patients can have and in the way they respond to treatment. Improvements made to treatment over the last decade have meant that survival rates are increasing, however there is still no cure and there remains a significant need for more efficacious and tolerable therapies. To this end, Oncopeptides needed an experienced partner to help take its promising molecule from the discovery phase through to clinical trials and finally commercial production.

Our team of experienced chemists were tasked with the challenge of finding a new formulation to improve the stability of Oncopeptides drug product, as well as assist as it passed through to the clinical development stages.

To find out how we helped, read the full case study here:

Advancing therapeutics for Myeloma